Diagnosis and management of invasive fungal infections: Focus on isavuconazole
10 Dec 2019
byAssoc Prof. Tan Ban Hock, Assoc Prof. Tan Thuan Tong, Assoc Prof. Andrea Kwa
Invasive fungal infections (IFIs), including aspergillosis and mucormycosis, are life-threatening and cause significant morbidity and mortality in patients. At a recent symposium, A/Prof Tan Ban Hock, Senior Consultant at the Department of Infectious Diseases, Singapore General Hospital (SGH), A/Prof Tan Thuan Tong, Senior Consultant and Head of Department, Infectious Diseases, SGH, and A/Prof Andrea Kwa, Clinician Scientist, Pharmacy, SGH, discussed the diagnosis and management of IFIs with a focus on isavuconazole (Cresemba®, Pfizer), a second-generation triazole indicated for the treatment of invasive aspergillosis (IA) and mucormycosis in adult patients for whom amphotericin B is inappropriate. Dr Yvonne Loh, Consultant Hematologist at Raffles Cancer Centre, chaired the event.